ALNYLAM PHARMACEUTICALS, INC. (ALNY) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
53/84
3.2 / 5 stars
All 84 Win/Lose results and 36 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 5 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/1 |
LoseALNY / S&P -9.02% / 15.20% |
No dataALNY / S&P / 15.00% |
No dataALNY / S&P / 50.40% |
| 2026-Q10/1 |
LoseALNY / S&P -16.79% / -4.33% |
No dataALNY / S&P / 11.30% |
No dataALNY / S&P / 27.70% |
| 2025-Q41/3 |
LoseALNY / S&P -12.80% / 2.65% |
WinALNY / S&P 65.19% / 9.00% |
LoseALNY / S&P -176.96% / 13.40% |
| 2025-Q32/3 |
WinALNY / S&P 39.84% / 8.12% |
WinALNY / S&P 53.24% / 4.61% |
LoseALNY / S&P -107.66% / 13.45% |
| 2025-Q23/3 |
WinALNY / S&P 20.77% / 10.94% |
WinALNY / S&P 5.01% / 4.83% |
WinALNY / S&P 325.42% / 10.63% |
| 2025-Q12/3 |
WinALNY / S&P 14.75% / -4.27% |
WinALNY / S&P 17.21% / 4.98% |
LoseALNY / S&P -21.72% / 10.57% |
| 2024-Q41/3 |
LoseALNY / S&P -14.44% / 2.41% |
WinALNY / S&P 22.97% / 5.25% |
LoseALNY / S&P -38.87% / 6.15% |
| 2024-Q32/3 |
WinALNY / S&P 13.18% / 5.89% |
WinALNY / S&P 21.54% / 5.89% |
LoseALNY / S&P -36.96% / 6.11% |
| 2024-Q22/3 |
WinALNY / S&P 62.60% / 4.28% |
WinALNY / S&P 89.46% / 5.38% |
LoseALNY / S&P -93.15% / 5.12% |
| 2024-Q11/3 |
LoseALNY / S&P -21.92% / 10.56% |
WinALNY / S&P 75.20% / 5.71% |
LoseALNY / S&P -69.28% / 5.59% |
| 2023-Q41/3 |
LoseALNY / S&P 8.08% / 11.69% |
WinALNY / S&P 76.23% / 6.81% |
LoseALNY / S&P -61.79% / 7.78% |
| 2023-Q31/3 |
LoseALNY / S&P -6.76% / -3.27% |
WinALNY / S&P 79.37% / 7.52% |
LoseALNY / S&P -57.63% / -5.03% |
| 2023-Q22/3 |
LoseALNY / S&P -5.18% / 8.74% |
WinALNY / S&P 39.94% / 9.50% |
WinALNY / S&P 5.39% / -8.57% |
| 2023-Q12/3 |
LoseALNY / S&P -15.71% / 7.50% |
WinALNY / S&P 29.94% / 10.77% |
WinALNY / S&P 16.02% / -15.69% |
| 2022-Q43/3 |
WinALNY / S&P 18.73% / 7.56% |
WinALNY / S&P 22.88% / 11.88% |
WinALNY / S&P 29.03% / -17.99% |
| 2022-Q33/3 |
WinALNY / S&P 37.24% / -4.88% |
WinALNY / S&P 28.24% / 13.47% |
WinALNY / S&P 37.03% / -1.41% |
| 2022-Q22/3 |
WinALNY / S&P -10.68% / -16.10% |
WinALNY / S&P 28.61% / 13.71% |
LoseALNY / S&P 7.64% / 11.04% |
| 2022-Q12/3 |
WinALNY / S&P -3.71% / -4.60% |
WinALNY / S&P 54.13% / 15.97% |
LoseALNY / S&P -0.66% / 42.23% |
| 2021-Q41/2 |
LoseALNY / S&P -10.18% / 11.03% |
WinALNY / S&P 71.31% / 15.00% |
No dataALNY / S&P / 96.40% |
| 2021-Q32/2 |
WinALNY / S&P 11.38% / 0.58% |
WinALNY / S&P 86.87% / 10.77% |
No dataALNY / S&P / 69.42% |
| 2021-Q22/2 |
WinALNY / S&P 20.07% / 8.55% |
WinALNY / S&P 99.18% / 6.58% |
No dataALNY / S&P / 51.81% |
| 2021-Q12/2 |
WinALNY / S&P 8.63% / 6.17% |
WinALNY / S&P 99.68% / -1.06% |
No dataALNY / S&P / 7.39% |
| 2020-Q41/2 |
LoseALNY / S&P -10.73% / 12.15% |
WinALNY / S&P 124.28% / -3.72% |
No dataALNY / S&P / -33.42% |
| 2020-Q31/2 |
LoseALNY / S&P -1.69% / 8.93% |
WinALNY / S&P 137.12% / -2.04% |
No dataALNY / S&P / -27.10% |
| 2020-Q22/2 |
WinALNY / S&P 36.07% / 20.54% |
WinALNY / S&P 241.39% / -0.46% |
No dataALNY / S&P / -27.11% |
| 2020-Q12/2 |
WinALNY / S&P -5.49% / -19.60% |
WinALNY / S&P 231.31% / 3.47% |
No dataALNY / S&P / -14.75% |
| 2019-Q42/2 |
WinALNY / S&P 43.21% / 9.07% |
WinALNY / S&P 193.36% / 5.36% |
No dataALNY / S&P / 2.99% |
| 2019-Q32/2 |
WinALNY / S&P 10.83% / 1.70% |
WinALNY / S&P 84.21% / 5.02% |
No dataALNY / S&P / 0.21% |
| 2019-Q20/2 |
LoseALNY / S&P -22.35% / 4.30% |
LoseALNY / S&P -5.35% / 6.64% |
No dataALNY / S&P / 8.65% |
| 2019-Q11/2 |
WinALNY / S&P 28.17% / 13.65% |
LoseALNY / S&P -7.05% / 8.12% |
No dataALNY / S&P / 14.29% |
| 2018-Q40/1 |
LoseALNY / S&P -16.69% / -13.52% |
No dataALNY / S&P / 9.05% |
No dataALNY / S&P / 18.23% |
| 2018-Q30/1 |
LoseALNY / S&P -11.14% / 7.71% |
No dataALNY / S&P / 10.21% |
No dataALNY / S&P / 19.06% |
| 2018-Q20/1 |
LoseALNY / S&P -17.30% / 3.43% |
No dataALNY / S&P / 9.03% |
No dataALNY / S&P / 14.46% |
| 2018-Q10/1 |
LoseALNY / S&P -6.26% / -0.76% |
No dataALNY / S&P / 7.68% |
No dataALNY / S&P / 12.46% |
| 2017-Q41/1 |
WinALNY / S&P 8.14% / 6.64% |
No dataALNY / S&P / 7.03% |
No dataALNY / S&P / 13.82% |
| 2017-Q31/1 |
WinALNY / S&P 47.30% / 4.48% |
No dataALNY / S&P / 5.68% |
No dataALNY / S&P / 17.57% |
| 2017-Q21/1 |
WinALNY / S&P 55.63% / 3.09% |
No dataALNY / S&P / 4.83% |
No dataALNY / S&P / 17.74% |
| 2017-Q11/1 |
WinALNY / S&P 36.89% / 6.07% |
No dataALNY / S&P / 3.67% |
No dataALNY / S&P / 13.32% |
| 2016-Q40/1 |
LoseALNY / S&P -44.76% / 3.82% |
No dataALNY / S&P / 2.09% |
No dataALNY / S&P / 7.05% |
| 2016-Q31/1 |
WinALNY / S&P 22.15% / 3.85% |
No dataALNY / S&P / 0.20% |
No dataALNY / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ALNY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -47.02% | 20.78% |
| Annualized return | -47.02% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ALNY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 20.06% | 83.14% |
| Annualized return | 3.72% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ALNY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 242.74% | 319.30% |
| Annualized return | 13.11% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |